Cancer & Immunotheraphy

 

 

With so much activity around cancer vaccines and immunotherapy right now, can you afford to miss out? It is the place where the global market will come together to share the latest in early-stage scientific advancements, present clinical trial data, discuss new formulations of cancer vaccines and assess the future of combination treatments. Make sure that people are aware of the work you are doing to put yourself at the forefront of the industry.

 

2018 AGENDA

 

Cancer & Immunotherapy, Wednesday 4 April 2018

Cancer & Immunotherapy
09:00

Chair’s opening remarks

Beyond Checkpoint Inhibitors

Dr Jay A. Berzofsky
Cancer & Immunotherapy
09:10

What’s next after PD1? Next generation checkpoint inhibitors including anti-TGF-beta

  • A deeper look at TGF-beta as a checkpoint inhibitor.
  • What are its effects on tumour growth and other cell types?
  • Synergy with vaccines and PD1 checkpoint inhibitors.
  • Brief look at other novel checkpoints, regulatory cells and cytokines; LAG3, Tim3
Panel discussion
Cancer & Immunotherapy
09:40

Panel Discussion: challenges to enhancing the therapeutic effectiveness of immune checkpoint antagonists with checkpoint agonists and inhibitors of immuno-metabolic pathways

  • Activating the antitumor immune T cell response through agonistic targets such as CD137 and OX40
  • Understanding the pathways used to create immune suppression and techniques to slow down immune suppression
  • What makes t-cell agonists so hard to work with vs checkpoint inhibitors?
10:40

Networking coffee break

Combination Therapy

Dr Roy Baynes
Cancer & Immunotherapy
11:40

PD-1 antibodies are transforming cancer therapy both as monotherapies and in combination

  • PD-1 antibody monotherapy indications continue to expand
  • PD-1 antibody has shown potential important activity when combined with:
    • Standard therapies e.g. chemotherapy
    • Targeted therapies e.g. with TKIs
    • Other immune modifying therapies e.g. IDO-1 inhibitors
    • Oncolytic viruses e.g. TVEC
  • Precision medicine will be increasingly important in patient selection
Cancer & Immunotherapy
12:10

Progress of combination studies using vaccines & checkpoint inhibitors in combination with other agents for the treatment of cancer

Dr Erin Karski
Cancer & Immunotherapy
12:40

Rapid and efficient development of combination therapies through a novel cancer immunotherapy platform.

  • Introduction to Morpheus; a novel cancer immunotherapy platform
  • How to go about selecting a combination study
  • Potential for use across several indications
1:10

Networking Lunch & Poster Session

Cancer Vaccines

Dr Michael Kalos
Cancer & Immunotherapy
2:40

State of the art and novel approaches to T Cell Vaccines

  • How have recent advances in immunotherapy provided a path forward for T-Cell Vaccines?
  • Biomarkers for T-cell strategies
Dr Douglas Mcneel
Cancer & Immunotherapy
3:10

Synergy of DNA Vaccines with checkpoint inhibitors

  • Selection of appropriate vaccine antigens for prostate cancer
  • Updates from ongoing translational trials of DNA vaccines in prostate cancer
Cancer & Immunotherapy
3:40

Novel oncolytic virus-based therapeutic cancer vaccines

4:10

Networking coffee break

Dr Michael Ciesielski
Cancer & Immunotherapy
4:40

Targeting cancer through SurVaxM, a new peptide immunotherapeutic vaccine

  • SurVaxM is a synthetic long peptide (SLP) vaccine with incorporated peptide mimic technology
  • Engineered to trigger a stronger immune response than wild type peptide, through better MHC binding 
  • Completed Phase 1 clinical trial in recurrent glioblastoma
  • Interim phase 2 data and designing a phase 3 trial
  • Exploring other indications and combination therapies
Panel discussion
Cancer & Immunotherapy
5:10

Panel Discussion: Tumor neoantigEn SeLection Alliance (TESLA) – discovering the keys to developing personalized cancer vaccines

  • Accurately identifying neo-epitopes
    • What is the diversity of neo-epitope predictions from different groups?
    • How well did these predictions perform in terms of patient sample analysis?
    • Can we identify key parameters that improve the ability to predict neo-epitopes?
  • How do we convert this data into the creation of personalized cancer vaccines?
    • Merits of different vaccines platforms
6:10

Chair’s closing remarks and close of congress day 2

6:15

Networking Drinks & Party

last published: 12/Dec/17 18:15

Cancer & Immunotherapy, Thursday 5 April 2018

Cancer & Immunotherapy
09:00

Chair’s opening remarks

Cancer Vaccines Continued

Dr Ildiko Csiki
Cancer & Immunotherapy
09:10

DNA vaccines for cancer immunotherapy

  • Introduction to DNA plasmid and electroporation delivery technology
  • Updates in proof of concept studies from various trials
  • Head and neck cancer, bladder cancer, prostate cancer
  • Examples of potential combination partners
  • The regulatory landscape for DNA Vaccines
Cancer & Immunotherapy
09:40

Overcoming the limitations of viral vectors whilst still maintaining superior generation and expansion of CTLs

Dr Lakshmi Krishnan
Cancer & Immunotherapy
09:55

Sulfated archael single lipid archaesome adjuvants for induction of cell mediated immunity against cancer vaccines

Dr Lakshmi Krishnan, Group Leader-Senior Research Officer, National Research Council

Oncoviruses

Cancer & Immunotherapy
10:10

Updates in the clinical development of an immunotherapy candidate for the treatment of chronic Hepatitis B

10:40

Networking coffee break

Dr Corey Casper
Cancer & Immunotherapy
11:30

Translational Studies Informing the Design and Feasibility of a vaccine against Epstein Barr Virus

  • Opportunities for the development of a vaccine against EBV
  • Understanding the medical necessity, market potential and public health use of EBV Vaccine.
  • The science behind the 3 vaccine candidates that currently exist:
    • Pre-clinical safety data
    • Updates on progress of phase 1 trials.
Dr Eliav Barr
Cancer & Immunotherapy
12:00

Advances in the development of a replication-deficient human cytomegalovirus vaccine for the prevention of congenital infection

12:30

Networking Lunch & Poster Session

AFTERNOON PLENARY OF CONGRESS

last published: 12/Dec/17 18:15

 

DOWNLOAD DRAFT AGENDA

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

 

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

 

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

 

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071